Patents Assigned to Schwarz Pharma, Inc.
  • Use of prostaglandin E1, E2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents
    Patent number: 5807895
    Abstract: A method of preventing renal failure or dysfunction caused by medical tests which utilize contrast media by administering, preferably by intravenous infusion or injection, a prostaglandin selected from PGE.sub.1, PGE.sub.2, PGI.sub.2 or an analog or pharmaceutically acceptable salt thereof and preferably in a form of a complex with .alpha.-cyclodextrin, to a patient at risk, for example, a diabetic.
    Type: Grant
    Filed: November 28, 1995
    Date of Patent: September 15, 1998
    Assignee: Schwarz Pharma, Inc.
    Inventors: Henry T. Stratton, Tammy K. Antonucci, Erwin Schollmayer